Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar by CNBC Markets | October 30, 2025 5:20 pm | US Markets The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
